FDA Single-Study Drug Approvals

What Does a Single-Study Drug Approval Pathway Mean?

Historically, the FDA has often required two adequate and well-controlled clinical trials to demonstrate that a drug is both safe and effective. The 1997 FDA Modernization Act formally allowed reliance on a single trial when supported by confirmatory evidence, and that flexibility has expanded in areas like oncology, rare diseases, and infectious disease. Reporting from The American Journal of Managed Care indicates the agency is now signaling a broader willingness to use a single-study standard to accelerate access to important new therapies.

In practical terms, a single pivotal trial can still be highly persuasive when it is large, well-randomized, double-blinded, and supported by strong mechanistic data, biomarker findings, or replication of effects across subgroups. Critics caution that not every disease area is suited to this approach, and that smaller datasets can leave open questions about long-term safety, durability of benefit, and performance in patients who differ from those enrolled in the pivotal trial.

How Will Post-Market Surveillance Protect Patients?

When the evidentiary bar at approval is lower, post-market surveillance becomes the safety net. The FDA's Sentinel System, adverse event reporting through FAERS, and postmarketing requirements (PMRs) under the Food and Drug Administration Amendments Act allow the agency to track signals once a drug is widely used. For accelerated approvals based on surrogate endpoints, sponsors are typically required to complete confirmatory trials to verify clinical benefit, with the option for the FDA to withdraw approval if those studies fail.

Patient and clinician groups have raised concerns about historical delays in completing these confirmatory trials, especially in oncology. A faster front-end approval process will likely intensify focus on enforcement of post-market commitments, transparent reporting of trial progress, and integration of real-world data from electronic health records and insurance claims. For prescribers and patients, that means shared decision-making conversations should explicitly address what is, and is not, yet known about a newly approved drug.

Which Patients Could Benefit Most From Faster Approvals?

The clearest case for streamlined approval is in conditions where patients cannot afford to wait through years of additional confirmatory studies — including aggressive cancers, neurodegenerative diseases, and ultra-rare genetic disorders where small patient populations make traditional two-trial programs impractical. The 21st Century Cures Act, signed in 2016, already encouraged use of novel trial designs and real-world evidence in such settings, and FDA officials have repeatedly stated that regulatory flexibility is essential for rare disease drug development.

At the same time, the same flexibility may be less appropriate for chronic conditions where existing therapies are already effective and where long-term safety in millions of users is the central question. Health economists and payers will be watching closely: faster approvals can compress evidence available at launch, complicating coverage and pricing decisions, especially when confirmatory data arrives years later.